Literature DB >> 12685858

The role of L-carnitine in treatment of a murine model of asthma.

Nevin Uzuner1, Salih Kavukçu, Osman Yilmaz, Selmin Ozkal, Hüray Işlekel, Ozkan Karaman, Alper Soylu, Aydanur Kargi.   

Abstract

Leukotrienes, one of the mediators of inflammation in asthma, have a strong bronchoconstrictive effect. L-carnitine has been reported to influence respiratory functions. It has also been reported that L-carnitine inhibits leukotriene synthesis. To evaluate the effects of L-carnitine on oxygen saturation, urine leukotriene E4 levels and lung histopathology in a murine model of asthma, high IgE responder BALB/c mice (n = 24) were systemically sensitized to ovalbumin and chronically challenged with low particle mass concentrations of aerosolized ovalbumin, and then they were divided into 3 groups (study groups A, B, and C) each including eight mice. After methacholine-induced bronchoconstriction, the mice in groups A and B were given intraperitoneal L-carnitine (250 and 125 mg/kg, respectively), while the mice in group C were given placebo. Oxygen saturation of the mice was measured by pulse oxymeter before and after methacholine and after L-carnitine/ placebo application. In addition, urine leukotriene E4 levels were measured before asthma development, and 24-h after L-carnitine injection in asthmatic mice. Inflammation in the lung tissues of the sacrificed animals was scored histopathologically to determine the effect of L-carnitine on tissue level. A control group of non-sensitized mice (n = 8) treated with placebo only was used for comparison of urine leukotriene E4 levels and of histopathological parameters. Oxygen saturation of the mice in the study groups tended to decrease after methacholine and to improve after L-carnitine injection, although these changes were not significant at all time points. Urine leukotriene E4 levels of all 3 study groups increased significantly after asthma development. The rate of increment was smallest in the group given the highest L-carnitine dose (group A). Inflammation at the tissue level was also mildest in group A, and severest in the group that was not given carnitine (group C). All of the study groups and the control group differed significantly with respect to inflammation scores. In conclusion, L-carnitine improved oxygen saturation, and decreased urine leukotriene E4 levels and inflammation in lung tissues in the present murine model of asthma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12685858     DOI: 10.18926/AMO/31692

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  5 in total

1.  Serum total and free carnitine levels in children with asthma.

Authors:  Suna Asilsoy; Ozlem Bekem; Ozkan Karaman; Nevin Uzuner; Salih Kavukçu
Journal:  World J Pediatr       Date:  2009-01-27       Impact factor: 2.764

2.  L-carnitine improves the asthma control in children with moderate persistent asthma.

Authors:  Mohammed Al-Biltagi; Mona Isa; Adel Salah Bediwy; Nevien Helaly; Dalia D El Lebedy
Journal:  J Allergy (Cairo)       Date:  2011-11-23

3.  Integrated associations of nasopharyngeal and serum metabolome with bronchiolitis severity and asthma: A multicenter prospective cohort study.

Authors:  Michimasa Fujiogi; Carlos A Camargo; Yoshihiko Raita; Zhaozhong Zhu; Juan C Celedón; Jonathan M Mansbach; Jonathan M Spergel; Kohei Hasegawa
Journal:  Pediatr Allergy Immunol       Date:  2021-03-04       Impact factor: 5.464

4.  Tissue metabolomic profiling to reveal the therapeutic mechanism of reduning injection on LPS-induced acute lung injury rats.

Authors:  Zhili Xiong; Yanmin Wang; Lang Lang; Shuping Ma; Longshan Zhao; Wei Xiao; Yanjuan Wang
Journal:  RSC Adv       Date:  2018-03-13       Impact factor: 4.036

5.  Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide-induced acute lung injury.

Authors:  Yanni Yang; Zihe Ding; Yi Wang; Renxing Zhong; Yanlin Feng; Tianyi Xia; Yuanyuan Xie; Bingyou Yang; Xiaobo Sun; Zunpeng Shu
Journal:  J Cell Mol Med       Date:  2020-03-27       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.